कंपनी का अवलोकन
Aurora Cannabis Inc. is engaged in the production, distribution, and sale of cannabis and cannabis-derivative products within Canada and international markets. The company operates through two primary segments, specifically Canadian Cannabis and Plant Propagation, offering pharmaceutical-grade cannabis products. This entity functions within the Healthcare sector and is classified under the Drug Manufacturers - Specialty & Generic industry, reflecting its focus on specialized medical-grade outputs rather than generic commodities. With a market capitalization of $197.35M and annual revenue of $373.12M, the company represents a mid-sized player in the evolving cannabis landscape. The revenue figure indicates a significant operational scale that generates substantial top-line activity, yet the relatively modest market cap suggests that the stock price reflects cautious investor sentiment regarding future profitability or growth sustainability. The absence of disclosed employee data (N/A) precludes a detailed assessment of workforce scale, but the revenue per implied employee would be high if the headcount is low, suggesting capital-intensive operations or a lean organizational structure typical of the industry. These valuation metrics collectively paint a picture of a company with established market presence but limited equity market valuation relative to its sales volume, a common characteristic in sectors facing regulatory or profitability headwinds.
वित्तीय स्वास्थ्य
The company reported a revenue of $373.12M over the trailing twelve months, while net income stood at -$83,512,000, and EBITDA was -$32,735,000. The substantial gap between the positive revenue of $373.12M and the negative net income of -$83.51M reveals a cost structure where operating expenses, including Cost of Goods Sold and administrative costs, significantly erode gross profits before taxes and interest. Despite the negative EBITDA of -$32.74M, the company generated positive free cash flow of $11.86M, which indicates a degree of financial flexibility allowing for operational continuity or strategic investments despite accounting losses. The gross margin stands at 36.0%, suggesting that the company retains a reasonable portion of revenue after direct production costs, though the operating margin of 2.3% and profit margin of -22.5% indicate high overhead burdens that suppress overall profitability. In terms of leverage, total cash holdings of $108.45M exceed total debt of $101.00M, resulting in a debt-to-equity ratio of 17.79, which technically indicates a leveraged balance sheet due to the high debt relative to equity, yet the positive cash cushion provides a critical buffer against liquidity shocks. The current ratio of 3.06 signifies strong short-term liquidity, demonstrating that the company holds more than three times the liquid assets required to cover its current liabilities. Furthermore, the return on equity is -15.5% and the return on assets is -4.4%, metrics that reveal management has yet to generate positive returns on the capital invested or deployed, highlighting challenges in converting revenue into shareholder value or asset appreciation.
मूल्यांकन आकलन
The P/E Ratio (TTM) is N/A due to negative earnings, while the forward P/E is -31.64, implying that the market is pricing in future earnings recovery or sustained losses. The price-to-book ratio is 0.51, indicating that the stock trades at approximately half of its book value, which suggests the market values the company's equity at a significant discount relative to its net asset position. The price-to-sales ratio of 0.53 and the EV/EBITDA of -6.76 provide alternative valuation perspectives; the low P/S ratio suggests the market is skeptical about revenue conversion to profit, while the negative EV/EBITDA reflects the company's current inability to generate operating cash flow from its assets. The stock's 52-week high is $6.67 and the 52-week low is $3.07; without a specific current price provided in the facts, the valuation context relies on these historical bounds which define the volatility range over the last year. The beta value of 1.32 indicates that the stock is 32% more volatile than the broader market, meaning price swings in ACB are expected to be amplified compared to large-cap healthcare or financial indices. This high beta, combined with the negative forward P/E, characterizes the asset as a high-risk, high-volatility investment suitable for portfolios with significant tolerance for equity fluctuations in the cannabis sector.
Growth & Income
Revenue growth year-over-year stands at 6.8%, whereas earnings growth year-over-year is -94.7%, indicating that earnings are contracting at a much faster rate than revenue is expanding. This divergence implies that while top-line sales are increasing through volume or price adjustments, cost control or margin expansion is failing to keep pace, leading to a severe deterioration in profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically available for reinvestment but are currently being consumed by losses. Consequently, the company reinvests its operational cash flow and retained earnings into business growth initiatives rather than distributing income to shareholders, a strategy typical for companies in the expansion phase of their lifecycle. The overall growth and income profile is characterized by positive revenue expansion offset by significant earnings contraction and a lack of dividend income, positioning the stock purely as a growth vehicle dependent on future operational turnarounds to restore profitability.